Carlos Trescolí

3.8k total citations
8 papers, 186 citations indexed

About

Carlos Trescolí is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Carlos Trescolí has authored 8 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Surgery and 2 papers in Molecular Biology. Recurrent topics in Carlos Trescolí's work include Diabetes Treatment and Management (7 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (3 papers). Carlos Trescolí is often cited by papers focused on Diabetes Treatment and Management (7 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (3 papers). Carlos Trescolí collaborates with scholars based in Spain, United States and France. Carlos Trescolí's co-authors include Yuan‐Di C. Halvorsen, Andrew S. Allegretti, Wenbin Zhang, Pierre Sérusclat, Tara Thurber, Mason W. Freeman, Wenjiong Zhou, Julio Rosenstock, Viswanathan Mohan and Rory J. McCrimmon and has published in prestigious journals such as Diabetes Care, American Journal of Kidney Diseases and Diabetes Obesity and Metabolism.

In The Last Decade

Carlos Trescolí

8 papers receiving 182 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos Trescolí Spain	7	182	73	52	21	13	8	186
Keith Bowering Canada	6	336 1.8×	130 1.8×	143 2.8×	31 1.5×	42 3.2×	12	342
Fredrik Thorén Sweden	10	269 1.5×	30 0.4×	202 3.9×	59 2.8×	8 0.6×	16	289
Masanori Togo Japan	4	111 0.6×	51 0.7×	54 1.0×	4 0.2×	11 0.8×	7	138
Sid McNulty United Kingdom	4	330 1.8×	93 1.3×	89 1.7×	84 4.0×	12 0.9×	13	361
Akemi Inagaki Japan	8	56 0.3×	53 0.7×	36 0.7×	38 1.8×	5 0.4×	13	149
Zsolt Gaál Hungary	7	104 0.6×	32 0.4×	41 0.8×	34 1.6×	8 0.6×	14	145
Xiaolin Dong China	8	181 1.0×	93 1.3×	36 0.7×	18 0.9×	38 2.9×	15	216
Ahmed Salem United Kingdom	5	85 0.5×	25 0.3×	44 0.8×	11 0.5×	15 1.2×	16	160
Mathilde Svendstrup Denmark	9	71 0.4×	61 0.8×	50 1.0×	42 2.0×	10 0.8×	16	202
Parag Singhal United Kingdom	4	44 0.2×	31 0.4×	38 0.7×	9 0.4×	8 0.6×	9	86

Countries citing papers authored by Carlos Trescolí

Since Specialization

Citations

This map shows the geographic impact of Carlos Trescolí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Trescolí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Trescolí more than expected).

Fields of papers citing papers by Carlos Trescolí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Trescolí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Trescolí. The network helps show where Carlos Trescolí may publish in the future.

Co-authorship network of co-authors of Carlos Trescolí

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Trescolí. A scholar is included among the top collaborators of Carlos Trescolí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Trescolí. Carlos Trescolí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Rosenstock, Julio, Rıfat Emral, Leobardo Sauque‐Reyna, et al.. (2021). Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care. 44(10). 2361–2370. 36 indexed citations

McCrimmon, Rory J., Rıfat Emral, Viswanathan Mohan, et al.. (2021). Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes Obesity and Metabolism. 23(6). 1221–1231. 23 indexed citations

Pérez, Antonio, et al.. (2020). Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. BMJ Open Diabetes Research & Care. 8(1). e001518–e001518. 10 indexed citations

Jude, Edward B., Carlos Trescolí, Rıfat Emral, et al.. (2020). Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study. Diabetes Obesity and Metabolism. 23(4). 929–937. 8 indexed citations

Allegretti, Andrew S., Wenbin Zhang, Wenjiong Zhou, et al.. (2019). Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. American Journal of Kidney Diseases. 74(3). 328–337. 58 indexed citations

Yale, J.‐F., Vanita R. Aroda, B Charbonnel, et al.. (2018). Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes & Metabolism. 46(2). 110–118. 19 indexed citations

Meneilly, Graydon S., Christine Roy-Duval, Hasan Alawi, et al.. (2017). Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 40(4). 485–493. 30 indexed citations

Meneilly, Graydon S., Hasan Alawi, George Dailey, et al.. (2016). Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706). Canadian Journal of Diabetes. 40(5). S45–S45. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact